Thursday, December 31, 2020

Most Read Cancer Currents Stories of 2020

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 
Dear Cancer Currents subscriber,

For most people, 2020 is a year they'd rather forget. But even as the COVID-19 pandemic unleashed disruption, chaos, and heartache, cancer researchers did their best to carry on with their work. And as some of the most popular stories published in Cancer Currents this year show, they continue to make important progress against cancer.

So, in case you missed any of these stories the first time around or want to share them with a friend, here are our most-read stories of 2020.

We'd also like to take this moment to thank you for your interest in and support of Cancer Currents. If you like what you're reading, please share our content with friends and colleagues and encourage them to subscribe.

Wishing you a happy and safe 2021.

The Cancer Currents editorial team

Top 5 Most Read

06/02/2020
A blood test combined with imaging tests detected tumors—some at an early stage—in women with no history of cancer or symptoms, a recent study showed. The test also mistakenly indicated some women had cancer when further testing showed they didn't.

05/11/2020
detecting-metastases-in-localized-prostate-cancer
For some men with prostate cancer at high risk of spreading, a large clinical trial shows an imaging method called PSMA PET-CT is more likely to detect metastatic tumors than the standard imaging approach used in many countries.

07/27/2020
CRISPR-Cas9-gene-editing
The gene-editing tool CRISPR is changing the way scientists study cancer, and may change how cancer is treated. This in-depth blog post describes how this revolutionary technology is being used to better understand cancer and create new treatments.

02/11/2020
proton-vs-imrt-lung-cancer
Some experts believe that proton therapy is safer than traditional radiation, but research has been limited. A new observational study compared the safety and effectiveness of proton therapy and traditional radiation therapy in adults with advanced cancer.

01/08/2020
Fluorescence-in-situ-hybridization
Tucatinib improved survival for women in the HER2CLIMB trial, including some whose cancer had spread to the brain. Trastuzumab deruxtecan improved survival and shrank many tumors in the DESTINY-Breast01 trial, which led to its accelerated approval.

Editors' Picks

01/28/2020
Immune-mediated-abscopal-effects
In people with cancer, the abscopal effect occurs when radiation—or another type of localized therapy—shrinks a targeted tumor but also causes untreated tumors in the body to shrink. Researchers are trying to better understand this phenomenon and take advantage of it to improve cancer therapy.

04/10/2020
HPV-costa-rica
More than a decade after vaccination, women who had received a single dose of the HPV vaccine continued to be protected against infection with the two cancer-causing HPV types targeted by the vaccine, an NCI-funded clinical trial shows.

10/26/2020
Radiopharmaceuticals-diagram
Researchers are developing a new class of cancer drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells. This Cancer Currents story explores the research on these emerging therapies.

04/30/2020
anxiety-depression-thoughts-survivors
Researchers are exploring ways to support the psychological and emotional needs of cancer survivors and how to tailor existing approaches to meet the needs of specific individuals or groups.

11/05/2020
deadliest cancer types 2012-2016
Diagnoses of colorectal cancer continue to increase in younger adults. In September 2020, more than 400 leading scientists and patient advocates participated in an NCI/National Institute of Environmental Health Sciences-sponsored symposium to identify research priorities that address important questions about this concerning trend.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment